List view / Grid view
US researchers develop a dual-action cell therapy engineered to eliminate established tumours and train the immune system to eradicate primary tumour and prevent cancer’s recurrence.
The scientists discovered that dual knockout of genes in organoids grown from human tissue can generate a model of a potential therapeutic target for gastroesophageal junction cancer.
Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
Sloan Kettering Institute (SKI) researchers have developed a new machete technique to slice into the cancer genome and study copy number alterations.
This article highlights five of the latest findings revealed using CRISPR that could be used in the development or design of new therapies.
US scientists, using CRISPR technology, removed specific genes in humans to allow the immune system to be more activated against cancer.
US researchers have engineered bacteriophages to deliver CRISPR-Cas payloads for targeted editing of a bacterium.
The researchers used a zebrafish model to test mutations in Mycn, a gene which causes Feingold syndrome.
In this Q&A, Dr Stephen Jones from Vilnius University Life Sciences Center discusses his work on the recent developments in genome editing tools at the university.
Deleting the gene POU2AF2 kills cancer cells in deadly subtype of small-cell lung cancer.
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
Genome editing technologies could accelerate the translation of genetic advances into new therapeutics. Here, Dr Pushpanathan Muthuirulan, Research Associate at Harvard University, explores the potential of CRISPR to treat and cure genetic conditions.
In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.
